PubMed Health⌕ Search

Biomedical subjects

M Fusaroli

Publications and source records attributed to M Fusaroli.

At least 37 records · Page 2Linked to original sources
PubMed1984

Renal osteodystrophy in CAPD patients.

To assess the influence of continuous ambulatory peritoneal dialysis (CAPD) on the evolution of renal osteodystrophy, we studied 36 adult patients with end-stage renal failure before starting dialysis and after 7-30 months. 17 patients (12 males and 5 females) were treated by CAPD as first treatment and 19 (14 males and 5 females) received maintenance hemodialysis. The two groups were age- and sex-matched and no patient received vitamin D. All patients had adequate clinical and metabolic follow-up with a radiological survey and quantitative bone histology at the start of dialysis and at the end of the study. Serum phosphate concentrations were much easier to control in CAPD than in hemodialysis patients. There was no difference in the evolutive pattern of vascular and periarticular calcifications in the two groups. The 25-hydroxyvitamin D3 levels were frequently lower in CAPD than in hemodialysis patients. In some CAPD patients, there was a significant loss of trabecular bone volume at the end of the study. The radiological and histological appearances of secondary hyperparathyroidism improved or seemed to worsen to a lesser degree in CAPD compared to hemodialysis patients.

Adult↗
PubMed1982

Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy.

The effects of long-term treatment with 25-hydroxycholecalciferol (25OHD3) and disodium ethane-1-hydroxydiphosphonate, or 25OHD3 alone on biochemical parameters, and radiographic and quantitative histomorphometry of bone tissue were evaluated in 17 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and defective mineralization of varying degree and predominance. 100 micrograms/day of 25OHD3 significantly improved the state of bone mineralization in many patients with a pronounced fall in the osteoid volume and surface and produced a small reduction in the active resorption surface. Serum parathyroid hormone (iPTH) and alkaline phosphatase levels decreased in some patients. The combination of 25OHD3 with EHDP caused the healing of bone mineralization as did 25OHD3 alone and produced a significant fall in serum alkaline phosphatase and iPTH. The mean magnitude of the reduction in iPTH was higher in patients treated with 25OHD3 and EHDP than with 25OHD3 alone. Treatment with 25OHD3 and EHDP seems more effective for the improvement of osteitis fibrosa than is 25OHD3 alone.

Adult↗
PubMed1978

Influence of ultrafiltration on plasma renin activity and adrenergic system.

The influence of efficient ultrafiltration without dialysis fluid was compared to the standard dialysis technique in two groups of 4 patients with chronic renal failure on maintenance haemodialysis. Supine plasma renin activity (PRA), plasma concentration of noradrenaline (NA), and adrenaline (A) and the Valsalva manoeuvre were determined before and after the period of ultrafiltration at the beginning and at the end of the experiment. The behaviour of these parameters was related to changes of blood pressure and body weight. The rapid weight loss was well tolerated during ultrafiltration only, with a significant increase of plasma catecholamines concentration; in contrast, patients treated with ultrafiltration and dialysis showed no significant increase of NA and A levels and they frequently became hypotensive. No relationship was observed between changes in PRA and those in body weight and blood pressure. Our data suggest that rapid removal of catecholamines during standard dialysis hinders the compensatory increase of the adrenergic activity and is responsible for hypotension.

Blood Pressure↗
PubMed1978

Treatment of ectopic calcification in uremia.

Nine uremic patients on maintenance hemodialysis who showed wide arterial and/or stable periarticular calcifications in spite of a well controlled hyperphosphatemia were treated with the diphosphonate disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) in doses of 7.5 to 10 mg/kg of body wt/per day for 5 to 9 months. No clinical or biochemical side-effects were noted. A significant reduction of the extent of periarticular calcifications was observed in five patients: two of them had a complete regression of soft-tissue calcifications, and one patient showed a reduction of arterial calcification. EHDP (7.5 to 10 mg/kg of body wt/per day) induced a significant increase of the osteoid volume and osteoid surface without significant modification of the calcification front. No evident effect on bone resorption and on the mineral content of the radius has been observed.

Adult↗
PubMed1975

[Periaticular metastatic calcifications in uremic patients].

Metastatic periarticular calcification was observed in 18 per cent of a series of 61 patients receiving haemodialytic treatment for from 3 months to over 5 yr. Calcium deposits occurred more frequently in the 1st and 2nd yr of treatment. The factors responsible included the plasma calcium-phosphorus product, non-optimal calcium and magnesium ion concentration in the dialysis bath, and secondary hyperparathyroidism. Tests for the diagnosis of parathyroid hyperfunction in the uraemic subject are described. The therapeutic criteria adopted in the prevention and management of calcification are also discussed.

Acidosis↗